Jade Biosciences (JBIO) Company presentation summary

Strategic focus and financial position

• Advancing three clinical candidates targeting autoimmune diseases with best-in-class potential and patient-friendly, infrequent dosing schedules.

• Well-funded with a cash runway extending into Q4 2028, supporting multiple upcoming clinical milestones.

• Exclusive license agreements in place for all pipeline assets from Paragon Therapeutics.

• Current capitalization includes 83.9 million shares outstanding as of June 30, 2026.

JADE101: Anti-APRIL mAb for IgA nephropathy (IgAN)

• Targets a $20B+ U.S. market with over 169,000 patients, addressing a high unmet need for effective, convenient, and disease-modifying therapies.

• Demonstrated favorable safety, well-tolerated profile, and robust, sustained IgA reductions (~70%) in Phase 1 healthy volunteers.

• Exhibits ultra-high APRIL binding affinity, extended half-life, and potential for every-12-week subcutaneous dosing.

• Phase 2 trial in IgAN patients initiated; interim data expected in 2027, with Phase 3 planned for 1H 2027.

JADE201: Afucosylated anti-BAFF-R mAb for systemic autoimmune diseases

• Dual mechanism enables deep, durable B cell depletion, overcoming resistance seen with anti-CD20 agents.

• Preclinical studies show high BAFF-R binding affinity, potent ADCC activity, and extended half-life.

• First-in-human Phase 1 trial in rheumatoid arthritis underway; interim data anticipated in 2027.

• Broad opportunity in multiple B cell-driven autoimmune indications, including lupus nephritis and Sjögren's disease.